摘要
目的:调查某院恶性肿瘤化疗患者使用重组人白介素-11(rhIL-11)的状况,评价使用rhIL-11的规范性。方法 :对某院2016年1月-2017年1月期间接受化疗并且使用过rhIL-11的204例患者用药情况进行回顾性分析,记录患者的个人信息、化疗方案及使用rhIL-11的情况,评价使用合理性。结果:从用药指征、剂量、疗程、停药指征及用药禁忌等方面综合评价,204例患者中52例应用rhlL-11与说明书或专家共识推荐用法完全相符。结论:目前某院rhIL-11的临床应用与说明书及专家共识存在较大差异,临床医师应更加规范的使用rhIL-11。
OBJECTIVE To investigate the clinical application of recombinant human interleukin-11（rhIL-11）in cancer patients with chemotherapy in our hospital,and standardize the evaluation of rhIL-11 use.METHODS In our hospital from January 2016 to January 2017,application of rhIL-11 for 204 patients was analyzed retrospectively.Normal information,disease related information,chemotherapy and rhIL-11 used in patients were recorded to evaluate the rationality of rhIL-11.RESULTSComprehensive evaluation was made on the medicinal indication,dosages,course of treatment,indications for withdrawal and contraindications of drugs for the patient.In 204 cases,52 cases of rhlL-11 use were consistent with the instructions or consensus.CONCLUSION In this hospital,there is a big difference in clinical application between instructions and expert consensus.The clinicians should standardize the use of rhIL-11.
作者
黎苏
霍虹
崔红霞
刘广宣
LI Su;HUO Hong;CUI Hong-xia;LIU Guang-xuan(Department of Pharmacy,Cancer Hospital of China Medical University,Liaoning Cancer Hospital ＆ Institute,Liaoning Shenyang 110042,China;Department of Pharmaceutics,School of Pharmacy,China Medical University,Liaoning Shenyang 110122,China)
出处
《中国医院药学杂志》
CAS
北大核心
2018年第14期1530-1533,1544,共5页
Chinese Journal of Hospital Pharmacy
关键词
重组人白介素-11
化疗所致血小板减少症
合理性评价
recombinant human interleukin-11
chemotherapy-induced thrombocytopenia
rationality evaluation
